Table 6 Logistic regression analysis of factors influencing recurrence at followed-up
Characteristics | Univariate model | Multivariate model | ||
|---|---|---|---|---|
OR (95% CI) | P value | OR (95% CI) | P value | |
Male gender | 1.35 (0.45–4.04) | 0.595 | ||
Age | 0.99 (0.94–1.06) | 0.955 | ||
Baseline HBsAg level | 0.99 (0.99–1.02) | 0.966 | ||
Treatment time | 1.01 (0.99–1.03) | 0.340 | ||
Consolidation time | 0.96 (0.91–1.01) | 0.097 | 0.92 (0.86–0.99) | 0.017 |
Anti-HBs positive | 0.32 (0.10-1.00) | 0.049 | 0.13 (0.03–0.52) | 0.004 |
IHC with PEG-IFN-α-2b monotherapy | 1.00 | |||
CHB with PEG-IFN-α-2b add-on ETV therapy | 0.30 (0.08–1.12) | 0.073 | ||
CHB with PEG-IFN-α-2b add-on TDF therapy | 0.62 (0.14–2.72) | 0.522 | ||
CHB with PEG-IFN-α-2b add-on TAF therapy | 0.58 (0.06–5.69) | 0.636 | ||
CHB with PEG-IFN-α-2b add-on TMF therapy | < 0.01 | 0.999 | ||
Blood routine test | ||||
White blood cells | 1.52 (1.05–2.20) | 0.029 | ||
Neutrophils | 2.12 (1.15–3.90) | 0.016 | ||
Platelets | 1.01 (0.99–1.02) | 0.183 | ||
Red blood cells | 3.13 (1.09–9.01) | 0.034 | ||
Hemoglobin | 1.01 (0.98–1.03) | 0.639 | ||
Liver function | ||||
ALT | 0.99 (0.96–1.02) | 0.413 | ||
AST | 0.96 (0.90–1.02) | 0.146 | ||
T-BIL | 1.06 (0.99–1.15) | 0.106 | ||
Total protein | 0.93 (0.84–1.03) | 0.147 | ||
Albumin | 0.90 (0.78–1.05) | 0.183 | ||
Globulin | 0.94 (0.84–1.05) | 0.270 | ||